Become A MemberEvent Registration
Close Menu
Chicago Innovation Award Winner

Novartis Gene Therapies

Winner in: 2020
Winning Product: Zolgensma
Winner Category: Chicago Innovation Award
Industry: Healthcare

Zolgensma® is designed to address the genetic root cause of SMA by providing a functional copy of the human SMN gene to halt disease progression through sustained SMN protein expression with a single, one-time IV infusion. Zolgensma was approved by the U.S. Food and Drug Administration in May 2019 and represents the first approved therapeutic in Novartis Gene Therapies’ proprietary platform to treat rare, monogenic diseases using gene therapy.5 In addition to the United States, Zolgensma is approved in Japan, Europe and Brazil. More than 600 patients have been treated with Zolgensma, including clinical trials, commercially and through the managed access program. Novartis Gene Therapies is pursuing registration in close to three dozen countries with regulatory decisions anticipated in Switzerland, Canada, Israel, Australia, and South Korea in late-2020 or early 2021.

Visit Website

Stay in the know on events &
news for Chicago innovators

Sign up to discover upcoming events and read the latest news about Chicago's innovators.

site by simple edge